180 related articles for article (PubMed ID: 31814497)
1. Results of Switching from Pro Re Nata to Treat-and-Extend Regimen in Treatment of Patients with Type 3 Neovascularization.
Kim JH
Semin Ophthalmol; 2020 Jan; 35(1):33-40. PubMed ID: 31814497
[No Abstract] [Full Text] [Related]
2. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
Kvannli L; Krohn J
Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
[TBL] [Abstract][Full Text] [Related]
3. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
[TBL] [Abstract][Full Text] [Related]
4. Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration.
Aurell S; Sjövall K; Paul A; Morén Å; Granstam E
Acta Ophthalmol; 2019 Aug; 97(5):519-524. PubMed ID: 30511374
[TBL] [Abstract][Full Text] [Related]
5. Effect of Pro Re Nata Regimen with Anti-VEGF on Type 3 Macular Neovascularization: Long-Term Outcomes.
Toto L; Viggiano P; Quarta A; Grassi M; De Nicola C; Aloia R; D'Aloisio R; Boscia G; Boscia F; Porreca A; Di Nicola M; Savastano MC; Mastropasqua R
Ophthalmic Res; 2024; 67(1):282-291. PubMed ID: 38621369
[TBL] [Abstract][Full Text] [Related]
6. Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study.
Augsburger M; Sarra GM; Imesch P
Graefes Arch Clin Exp Ophthalmol; 2019 Sep; 257(9):1889-1895. PubMed ID: 31256237
[TBL] [Abstract][Full Text] [Related]
7. A Trinity regimen with aflibercept for treatment-naïve neovascular age-related macular degeneration: 2-year outcomes.
Wakuta M; Nomi N; Ogata T; Ota M; Yamashiro C; Hatano M; Yanai R; Tokuda K; Kimura K
Graefes Arch Clin Exp Ophthalmol; 2020 Aug; 258(8):1663-1670. PubMed ID: 32436085
[TBL] [Abstract][Full Text] [Related]
8. Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration: A Prospective Study.
Maruko I; Ogasawara M; Yamamoto A; Itagaki K; Hasegawa T; Arakawa H; Nakayama M; Koizumi H; Okada AA; Sekiryu T; Iida T
Ophthalmol Retina; 2020 Aug; 4(8):767-776. PubMed ID: 32417356
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial.
Feltgen N; Bertelmann T; Bretag M; Pfeiffer S; Hilgers R; Callizo J; Goldammer L; Bemme S; Hoerauf H
Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):923-934. PubMed ID: 28102456
[TBL] [Abstract][Full Text] [Related]
10. 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting.
Vardarinos A; Gupta N; Janjua R; Iron A; Empeslidis T; Tsaousis KT
BMC Ophthalmol; 2017 Apr; 17(1):58. PubMed ID: 28449645
[TBL] [Abstract][Full Text] [Related]
11. Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?
Patel Y; Miller DM; Fung AE; Hill LF; Rosenfeld PJ
Ophthalmol Retina; 2020 Feb; 4(2):141-147. PubMed ID: 31735634
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab.
Elwes F; Borooah S; Aspinall P; Sim PY; Loo CY; Armbrecht AM; Dhillon B; Cackett P
BMC Ophthalmol; 2018 Jan; 18(1):20. PubMed ID: 29378528
[TBL] [Abstract][Full Text] [Related]
13. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.
Abdin AD; Suffo S; Asi F; Langenbucher A; Seitz B
Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1671-1677. PubMed ID: 31144055
[TBL] [Abstract][Full Text] [Related]
15. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study.
Saenz-de-Viteri M; Recalde S; Fernandez-Robredo P; López Gálvez MI; Arias Barquet L; Figueroa MS; García-Arumí J; García-Layana A;
Acta Ophthalmol; 2021 Dec; 99(8):861-870. PubMed ID: 33720541
[TBL] [Abstract][Full Text] [Related]
16. Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study.
Hatz K; Prünte C
Acta Ophthalmol; 2017 Feb; 95(1):e67-e72. PubMed ID: 27009503
[TBL] [Abstract][Full Text] [Related]
17. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL
JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617
[TBL] [Abstract][Full Text] [Related]
18. Treat-and-extend versus every-other-month regimens with aflibercept in age-related macular degeneration.
Haga A; Kawaji T; Ideta R; Inomata Y; Tanihara H
Acta Ophthalmol; 2018 May; 96(3):e393-e398. PubMed ID: 29220114
[TBL] [Abstract][Full Text] [Related]
19. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
Jørstad ØK; Faber RT; Moe MC
Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
[TBL] [Abstract][Full Text] [Related]
20. Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections.
Osaka R; Muraoka Y; Miwa Y; Manabe K; Kobayashi M; Takasago Y; Ooto S; Murakami T; Suzuma K; Iida Y; Tsujikawa A
Ophthalmologica; 2018; 239(1):27-35. PubMed ID: 28946138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
